Everolimus is a selective inhibitor of the mTOR-signaling pathway and consequently, of growth and proliferation of cells involved in TSC, in addition to reduction of glutamatergic excitation.[3] Thus, everolimus is considered a precision drug with antiepileptogenic properties.[4–6] The efficacy of everolimus for focal seizures in patients with epilepsy secondary to TSC was demonstrated in a randomized clinical trial (EXIST-3).[4] Everolimus is approved as adjunctive treatment for patients from 2 years with TSC and refractory focal seizures.[7]. This evidence concerns the gene MTOR and epilepsy.